Relapsed and/or refractory b-cell lymphoma
Drug research and approvals for relapsed and/or refractory b-cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 189 studies of relapsed and/or refractory b-cell lymphoma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 15 drug trials for it since 2013.
- Recruiting worldwide: 189
- Trials authorized in Canada: 15
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 189 recruiting on ClinicalTrials.gov ↗- Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic…NCT07758673 · Phase 1 · City of Hope Medical Center · starts Apr 17, 2027
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute…NCT07936266 · Phase 1 · Sunil G. Iyer · starts Mar 31, 2027
- A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell MalignanciesNCT07735533 · Phase 1 / Phase 2 · Umoja Biopharma · starts Nov 1, 2026
- Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple MyelomaNCT07725406 · Phase 1 · Weill Medical College of Cornell University · starts Nov 1, 2026
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasNCT07883135 · Phase 2 · National Research Center for Hematology, Russia · starts Sep 1, 2026
- Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or LymphomaNCT07532525 · Phase 1 · University of Michigan Rogel Cancer Center · starts Aug 26, 2026
- Glofitamab as a Bridge to and/or Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell…NCT07387848 · Phase 2 · American University of Beirut Medical Center · starts Aug 24, 2026
- CD45BE-HSPC + CART-45 CellsNCT07451054 · Phase 1 · University of Pennsylvania · starts Aug 5, 2026
- GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic LeukemiaNCT07910708 · Phase 1 · Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital · starts Aug 4, 2026
- A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLLNCT07609823 · Phase 2 · Guangzhou Lupeng Pharmaceutical Company LTD. · starts Jul 14, 2026
Trials Authorized in Canada
The 10 newest of 15; search them all in Canada trials| Mar 11, 2026 | A phase 1/2 open-label, multicenter study evaluating the safety and efficacy of kite-363 or kite-753, autologous anti-cd19/cd20 car t-cell therapies, in…KITE-753 | KITEPHARMA INC | Ongoing |
| Feb 20, 2026 | A phase 3 randomized controlled trial of rondecabtagene autoleucel, an autologous, dual-targeting cd19/cd20 car t-cell product candidate, versus investigator’s…RONDECABTAGENE AUTOLEUCEL | LYELL IMMUNOPHARMA, INC | Ongoing |
| Dec 13, 2024 | A phase II, open-label, multicenter study to evaluate the optimization of the cytokine release syndrome profile for glofitamab in combination with gemcitabine…COLUMVI / GAZYVA | Roche | Ongoing |
| Jul 2, 2024 | An open-label, phase I/ii study to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of englumafusp alfa (ro7227166, a cd19 targeted…ENGLUMAFUSP ALFA (RO7227166) / GLOFITAMAB / GAZYVA / ACTEMRA (FOREIGN-MARKET… | Roche | Ongoing |
| Jun 13, 2024 | Relapsed or refractory diffuse large b-cell lymphoma: phase 3 study to evaluate the safety and efficacy of epcoritamab plus lenalidomide compared to rituximab…EPCORITAMAB / LENALIDOMIDE / RITUXIMAB / GEMCITABINE / OXALIPLATIN / TOCILIZUMAB | AbbVie | Ongoing |
| Nov 30, 2023 | Expanded access protocol (eap) for subjects receiving lisocabtagene maraleucel that is nonconforming to commercial releaseBREYANZI (LISOCABTAGENE MARALEUCEL (JCAR017)) | Bristol-Myers Squibb | Ongoing |
| Dec 22, 2022 | A single-arm, open-label, phase 1/2 study evaluating the safety, efficacy, and cellular kinetics/pharmacodynamics of allo-501a, an anti-cd-19 allogeneic car t…ALLO-501A / ALLO-647 / FLUDARABINE PHOSPHATE / CYCLOPHOSPHAMIDE | ALLOGENE THERAPEUTICS INC | Ongoing |
| Feb 25, 2022 | A phase 2 non-randomized, open-label, multi-cohort, multicenter study assessing the clinical benefit of sar444245 (thor-707) with or without other anticancer…SAR444245 / TOCILIZUMAB / PEMBROLIZUMAB | SANOFI-AVENTIS CANADA INC | Closed |
| Jun 23, 2021 | An open-label, phase 2 trial of nanatinostat in combination with valganciclovir in patients with epstein-barr virus-positive (ebv+) relapsed/refractory…NANATINOSTAT/ VALGANCICLOVIR/ GANCICLOVIR | VIRACTA THERAPEUTICS INC. | Closed |
| Mar 4, 2020 | A phase 1/2, open-label, dose-escalation trial of gen3013 in patients with relapsed, progressive or refractory b-cell lymphomaGEN3013 (DUOBODY-CD3XCD20) | Genmab | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA